Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

The idea is management is confident ... Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them.

Medical Watch for Sept 10 Weekly insulin proves as effective as daily for Type 1 patients Some welcome news for diabetics. New research published in the Lancet Medical Journal reveals a new class ...

Weight-management treatments are all the rage lately. According to Morgan Stanley, combined sales of injections that curb appetites and promote weight loss could reach an estimated $105 billion by ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and ...

I don't think Novo Nordisk is a stock to sell right now, but if you're looking to buy just one of the pair, Eli Lilly has a bit more momentum. The Motley Fool Stock Advisor analyst team just ...